Coverage dated October 28, 2026 to November 2, 2026
RFK Jr. eases access to unproven peptides despite opposition from FDA scientists
Headline from WATE Knoxville
The document, primarily written by officials at HHS, faced overwhelming pushback among FDA drug staffers who warned it could undermine the agency’s long-standing mission of keeping unsafe health products off the U.S. market
WATE Knoxville's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
WASHINGTON (AP) — A plan to give Americans easier access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr. was opposed by most Food and Drug Administration scientific staff members, who had limited input in drafting the policy, according to six people familiar with the poli…
The Department of Health and Human Services is giving compounding pharmacies a temporary green light to make six peptides while the agency continues to work on a formal rule change.
The document, primarily written by officials at HHS, faced overwhelming pushback among FDA drug staffers who warned it could undermine the agency’s long-standing mission of keeping unsafe health products off the U.S. market
Food and Drug Administration scientists didn't support a new policy by President Donald Trump's administration to loosen rules on unproven peptide drugs. That's according to people familiar with the policy’s development who were interviewed by The Associated Press.
A plan to give Americans easier access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr. was opposed by most Food and Drug Administration scientific staff members, who had limited input in drafting the policy, according to six people familiar with the policy’s development.
Effort to loosen rules on unproven peptide drugs, favored by RFK Jr, faced fierce pushback from agency scientists A plan to give people in the United States easier access to unproven peptide drugs favored by the US health secretary, Robert F Kennedy Jr , was opposed by most Food and Drug Administrat…
A plan to give people in the United States easier access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr. was opposed by most Food and Drug Administration scientific staff members, who had limited input in drafting the policy, according to six people familiar with its deve…
The draft policy posted online by RFK Jr.’s Department of Health and Human Services covers a handful of injectable peptides promoted within the wellness industry.
Health and Human Services Secretary Robert F. Kennedy Jr. took steps Wednesday that could open up access to certain unapproved peptide drugs that are being promoted for wellness.
WASHINGTON -- The Trump administration on Wednesday acted to ease access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr. Food and Drug Administration scientific staffers had little input on the decision and opposed the changes, according to six people familiar with its de…
U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday pushed forward a policy allowing licensed pharmacies and physicians to compound certain unapproved peptides while regulators consider whether to formally permit their use in compounded medicines.
